Skip to main content

Table 6 Univariate Cox regression model of clinical parameters on disease specific survival in stratified high-grade serous carcinoma (HGSC)

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

  All HGSC Advanced stage HGSC Poor prognosis HGSC Low Stage HGSC
Hazard 95.0% CI    Hazard 95.0% CI    Hazard 95.0% CI    Hazard 95.0% CI   
Ratio Lower Upper n p value Ratio Lower Upper n p value Ratio Lower Upper n p value Ratio Lower Upper n p value
BRCA mutation carrier statusa
 Non carrier     351 reference     293 reference     236 reference     61 reference
 BRCA1 carrier 0.62 0.44 0.88 67 0.007 0.65 0.44 0.95 45 0.029 0.79 0.51 1.20 32 0.268 0.92 0.40 2.11 21 0.849
 BRCA2 carrier 0.42 0.24 0.72 34 0.002 0.41 0.22 0.76 26 0.004 0.39 0.20 0.77 21 0.006 0.80 0.19 3.44 7 0.766
 All mutated vs no mutation 0.56 0.42 0.76 472 0.000 0.57 0.41 0.80 375 0.001 0.64 0.44 0.93 294 0.02 0.82 0.37 1.81 85 0.78
Chemotherapy treatment type
 Carboplatinum+taxane     940 reference     727 reference     469 reference     167 reference
 Cisplatinum+taxane 1.14 0.87 1.50 71 0.348 0.63 0.44 0.89 67 0.728 1.11 0.83 1.49 60 0.495 NA NA NA 4 NA
 Platinum 1.86 1.37 2.52 63 0.000 0.42 0.24 0.73 46 0.000 2.65 1.83 3.83 38 0.000 1.65 0.71 3.84 13 0.245
 Platinum+other 1.93 1.35 2.75 38 0.000 0.56 0.42 0.76 33 0.005 1.44 0.94 2.19 28 0.093 NA NA NA 3 NA
Provinces
 Quebec     584 reference     472 reference     275 reference   Lower Upper NA  
 Ontario 0.80 0.66 0.98 195 0.034 0.69 0.54 0.88 119 0.003 0.77 0.58 1.03 89 0.074 NA NA NA NA NA
 Alberta 0.71 0.56 0.91 120 0.007 0.73 0.56 0.96 88 0.025 0.51 0.34 0.78 41 0.002 NA NA NA NA NA
 Manitoba 0.46 0.15 1.45 10 0.185 0.20 0.03 1.45 7 0.111 NA NA NA 6 NA NA NA NA NA NA
 British Columbia 0.99 0.84 1.17 307 0.917 1.02 0.86 1.21 248 0.841 1.21 0.99 1.47 210 0.064 NA NA NA NA NA
  1. Bold values highlights the statistically significant difference with the reference category
  2. NA non applicable, number of cases too low, n number of patients with follow-up, HR Hazard ratio
  3. a platinum-based patients only, low stage: disease stage I and II, advanced stage: disease stage III and IV